Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-55 Mln
-
ROE
-1.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
4,902,260
10 Years Aggregate
CFO
$-214.35 Mln
EBITDA
$-218.41 Mln
Net Profit
$-241.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
| -98.2 | -47.2 | -94.4 | -98.9 | -86.3 | -80.1 | -- |
|
BSE Sensex*
| -9.7 | -0.2 | -7.0 | -6.4 | 7.4 | 8.6 | 11.7 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
| -10.8 | -65.3 | -28.3 | -79.4 | -33.3 | -65.8 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.3 | 2.7 | 0.7 | -55.2 | -8,350.1 | -211.2 | -- | 0.2 |
| 18.2 | 1,075.9 | 0.0 | -167.9 | -- | -128.7 | -- | 5.2 | |
| 26.9 | 16,496.4 | 8,837.9 | 2,614.3 | 36.5 | 45.7 | 20.5 | 2.9 | |
| 12.0 | 2,061.7 | 550.0 | 458.1 | -3.3 | 45.9 | 4.5 | 1.7 | |
| 5.1 | 1,059.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.2 | 1,965.1 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.4 | |
| 12.6 | 889.9 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.3 | 3.3 | |
| 3.0 | 536.4 | 4.0 | -198.4 | -5,037.7 | -166.3 | -- | 7.0 | |
| 17.5 | 419.9 | 4.7 | -109.7 | -- | -30.2 | -- | 1.4 | |
| 18.6 | 2,090.9 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Zosano Pharma (ZSAN)
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta... (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Sr. VP of Operations, Pres, CEO & Director
Mr. Steven Lo
-
Sr. VP of Operations, Pres, CEO & Director
Mr. Steven Lo
-
Headquarters
Fremont, CA
-
Website
FAQs for Zosano Pharma (ZSAN)
What is the current share price of Zosano Pharma Corporation (ZSAN) Today?
The share price of Zosano Pharma Corporation (ZSAN) is $0.30 (NASDAQ) as of 08-Jul-2022 09:30 EDT. Zosano Pharma Corporation (ZSAN) has given a return of -86.28% in the last 3 years.
What is the current PB & PE ratio of Zosano Pharma Corporation (ZSAN)?
Since, TTM earnings of Zosano Pharma Corporation (ZSAN) is negative, P/E ratio is not available.
The P/B ratio of Zosano Pharma Corporation (ZSAN) is 0.16 times as on 08-Jul-2022, a 97 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Zosano Pharma Corporation (ZSAN)?
The 52-week high and low of Zosano Pharma Corporation (ZSAN) are Rs -- and Rs -- as of 25-May-2026.
What is the market cap of Zosano Pharma Corporation (ZSAN)?
Zosano Pharma Corporation (ZSAN) has a market capitalisation of $ 3 Mln as on 08-Jul-2022. As per SEBI classification, it is a company.
Should I invest in Zosano Pharma Corporation (ZSAN)?
Before investing in Zosano Pharma Corporation (ZSAN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.